Patents by Inventor Michael A. Dyer

Michael A. Dyer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170297630
    Abstract: An integrated fastener for an instrument cluster assembly, where multiple integrated fasteners are used to connect the front cover of the assembly to the back cover. The instrument cluster assembly includes at least one fastener integrated into the back cover, a first recessed portion formed as part of the back cover, and a separation wall formed as part of the back cover in proximity to the first recessed portion. A first mounting aperture is formed as part of the separation wall, and the integrated fastener attached to the back cover and located in the first mounting aperture when the integrated fastener is in a first configuration. The integrated fastener is detached from the back cover and rotated such that the integrated fastener is placed in a second configuration, securing the front cover to the back cover.
    Type: Application
    Filed: April 7, 2017
    Publication date: October 19, 2017
    Applicant: Continental Automotive Systems, Inc.
    Inventors: Daniel P. Tollis, Francisco Bolanos Ramirez, Michael E. Carrel, Fernando De Anda Gonzalez, Kevin Michael Dyer, Augusto Guillermo Figueroa Tamayo, Johan Gomez Martinez, Aldo Sainz Hernandez
  • Publication number: 20160297800
    Abstract: The compounds of the invention are antagonists of MDM2 and MDMX, with excellent specificity for MDM2 and MDMX over other proteins, and with selective binding affinity to MDMX over MDM2. The compounds can therefore regulate p53 activity and treat a variety of cancers. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: January 8, 2016
    Publication date: October 13, 2016
    Inventors: R. Kiplin Guy, Yiqun Zhang, Brandon Young, Michael Dyer, Kristin Finch, Donald Bashford, Nagakumar Bharatham, Richard Kriwacki, Grace Roy-Appa, Lie Min, Jaeki Min, Antonio Ferreira
  • Patent number: 9266860
    Abstract: The compounds of the invention are antagonists of MDM2 and MDMX, with excellent specificity for MDM2 and MDMX over other proteins, and with selective binding affinity to MDMX over MDM2. The compounds can therefore regulate p53 activity and treat a variety of cancers. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: February 23, 2016
    Assignee: St. Jude Children's Research Hospital
    Inventors: R. Kiplin Guy, Yiqun Zhang, Brandon Young, Michael Dyer, Kristin Finch, Donald Bashford, Nagakumar Bharatham, Richard Kriwacki, Grace Roy-Appa, Lie Min, Jaeki Min, Antonio Ferreira
  • Patent number: 9078895
    Abstract: It has now been found that the p53 pathway is inactivated in ocular cancers such as retinoblastoma. As such, the present invention is a method for inducing ocular cancer cell death using a p53 activator. In particular embodiments, the p53 activator blocks the interaction between DM2 or DMX and p53. As the p53 activator induces ocular cancer cell death, a method for preventing or treating ocular cancer is also provided.
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: July 14, 2015
    Assignees: St. Jude Children's Research Hospital, Flanders Interuniversity Institute for Biotechnology, Universiteit Gent, Leiden University Medical Center
    Inventors: Michael A. Dyer, Jean-Christophe Marine, Aart Gerrit Jochemsen
  • Publication number: 20140121218
    Abstract: It has now been found that the p53 pathway is inactivated in ocular cancers such as retinoblastoma. As such, the present invention is a method for inducing ocular cancer cell death using a p53 activator. In particular embodiments, the p53 activator blocks the interaction between DM2 or DMX and p53. As the p53 activator induces ocular cancer cell death, a method for preventing or treating ocular cancer is also provided.
    Type: Application
    Filed: December 5, 2013
    Publication date: May 1, 2014
    Applicants: St. Jude Children's Research Hospital, Leiden University Medical Center, Universiteit Gent, Flanders Interuniversity Institute for Biotechnology VIB
    Inventors: Michael A. Dyer, Jean-Christopher Marine, Aart Gerrit Jochemsen
  • Publication number: 20130345237
    Abstract: The compounds of the invention are antagonists of MDM2 and MDMX, with excellent specificity for MDM2 and MDMX over other proteins, and with selective binding affinity to MDMX over MDM2. The compounds can therefore regulate p53 activity and treat a variety of cancers. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: September 30, 2011
    Publication date: December 26, 2013
    Inventors: R. Kiplin Guy, Yiqun Zhang, Brandon Young, Michael Dyer, Kristin Finch, Donald Bashford, Nagakumar Bharatham, Richard Kriwacki, Grace Royappa, Lie Min, Jaeki Min, Anthony Ferreira
  • Patent number: 8614192
    Abstract: It has now been found that the p53 pathway is inactivated in ocular cancers such as retinoblastoma. As such, the present invention is a method for inducing ocular cancer cell death using a p53 activator. In particular embodiments, the p53 activator blocks the interaction between DM2 or DMX and p53. As the p53 activator induces ocular cancer cell death, a method for preventing or treating ocular cancer is also provided.
    Type: Grant
    Filed: July 24, 2007
    Date of Patent: December 24, 2013
    Assignees: Leiden University Medical Center, Flanders Interuniversity Institute for Biotechnology, VIB, St. Jude Children's Research Hospital
    Inventors: Michael A. Dyer, Jean-Christophe Marine, Aart Gerrit Jochemsen
  • Patent number: 8470785
    Abstract: Compositions and methods for treating ocular cancer are provided. The composition is a subconjunctival formulation of nutlin-3 and its analogs. The composition provides for methods of treating ocular cancer, including retinoblastoma. The formulation has high penetration into ocular tissue with low toxicity.
    Type: Grant
    Filed: September 27, 2011
    Date of Patent: June 25, 2013
    Assignees: St. Jude Children's Research Hospital, Leiden University Medical Center, VIB VZW and Universiteit Gent
    Inventors: Michael A. Dyer, Jean-Christophe Marine, Aart Gerrit Jochemsen, R. Kip Guy, Fangyi Zhu
  • Publication number: 20120115880
    Abstract: Compositions and methods for treating ocular cancer are provided. The composition is a subconjunctival formulation of nutlin-3 and its analogs. The composition provides for methods of treating ocular cancer, including retinoblastoma. The formulation has high penetration into ocular tissue with low toxicity.
    Type: Application
    Filed: September 27, 2011
    Publication date: May 10, 2012
    Applicant: St. Jude Children's Research Hospital
    Inventors: Michael A. Dyer, Jean-Christophe Marine, Aart Gerrit Jochemsen, R. Kip Guy
  • Publication number: 20090298785
    Abstract: It has now been found that the p53 pathway is inactivated in ocular cancers such as retinoblastoma. As such, the present invention is a method for inducing ocular cancer cell death using a p53 activator. In particular embodiments, the p53 activator blocks the interaction between DM2 or DMX and p53. As the p53 activator induces ocular cancer cell death, a method for preventing or treating ocular cancer is also provided.
    Type: Application
    Filed: July 24, 2007
    Publication date: December 3, 2009
    Inventors: Michael A. Dyer, Jean-Christophe Marine, Aart Gerrit Jochemsen
  • Publication number: 20080241780
    Abstract: The present invention generally provides a system for warming an outdoor surface. The system includes a heat exchange unit to provide heated air for use across the surface to melt snow or ice or to warm, evaporate or distribute water. The heat exchange unit is used to recapture the heated air. The present invention also generally provides a method of warming an outdoor surface. The method comprises the steps of providing heated air across the surface to melt snow or ice or to warm, evaporate or distribute water, recapturing the heated air, and redistributing the heated air across the surface.
    Type: Application
    Filed: March 28, 2008
    Publication date: October 2, 2008
    Inventor: Michael Dyer
  • Patent number: 7023401
    Abstract: An antenna reflector and an associated latch system are provided. The antenna reflector includes a plurality of reflector portions that are connected in a predetermined configuration to define a continuous surface, such as a parabolic surface. The latches connect the reflector portions. Each latch includes first and second latch members, which define reference surfaces that are structured to contact when the latch is closed. In particular, the reference surfaces are disposed at predetermined and dissimilar distances from connection features of the respective latch members. For example, the first and second reference surfaces of the respective latch members can be disposed at first and second distances from apertures through the respective latch members. The first distance can be greater than the second distance so that, when a fastener is disposed through both apertures, the reference surfaces are urged together and the reflector portions are connected in a predetermined configuration.
    Type: Grant
    Filed: July 9, 2004
    Date of Patent: April 4, 2006
    Assignee: Vertexrsi
    Inventors: Keith Edward Thrash, Michael Dyer, Jeremy Bartell
  • Publication number: 20060007050
    Abstract: An antenna reflector and an associated latch system are provided. The antenna reflector includes a plurality of reflector portions that are connected in a predetermined configuration to define a continuous surface, such as a parabolic surface. The latches connect the reflector portions. Each latch includes first and second latch members, which define reference surfaces that are structured to contact when the latch is closed. In particular, the reference surfaces are disposed at predetermined and dissimilar distances from connection features of the respective latch members. For example, the first and second reference surfaces of the respective latch members can be disposed at first and second distances from apertures through the respective latch members. The first distance can be greater than the second distance so that, when a fastener is disposed through both apertures, the reference surfaces are urged together and the reflector portions are connected in a predetermined configuration.
    Type: Application
    Filed: July 9, 2004
    Publication date: January 12, 2006
    Inventors: Keith Thrash, Michael Dyer, Jeremy Bartell
  • Publication number: 20050086708
    Abstract: Complimentary animal models for retinoblastoma which recapitulate conditions found in the eye of human retinoblastoma patients in an animal are provided. These models are generated by introducing an agent capable of giving rise to a retinoblastoma into the developing eye of an immunologically naive animal. In one model the agent comprises cells which are capable of giving rise to a retinoblastoma. In another model the agent comprises a vector capable of expressing an oncogene which, when expressed in a transfected cell, can give rise to a cell mass that mimics the early stages of retinoblastoma formation. These models can be used to study retinoblastoma and screen for, or characterize, inhibitory agents. These models may also be used to study the influence of genotype or engineered genes or gene deficiencies (knock-outs) on the development of retinoblastoma.
    Type: Application
    Filed: October 12, 2004
    Publication date: April 21, 2005
    Inventor: Michael Dyer
  • Patent number: 6557852
    Abstract: Cubic senary (base 6) dice uniquely harness the power of the base 6 number system and generate random numbers from a predetermined set of consecutive numbers, each tending to occur with the same relative frequency. Cubic senary dice have numerical values corresponding to the place values of the base 6 number system, and face values corresponding to the senary notational digits (0, 1, 2, 3, 4, 5). Notational digits on cubic senary dice have two values: an intrinsic value—which is that signified by the isolated symbol itself, and a local value—the value possessed by the numeral by virtue of the power of its die, 60, 61, 62, etc. The magnitude of the senary number cast is a sum of products involving powers of the number 6. A random senary number is obtained by casting the dice and reading the notational digits returned from each die cast, in order, from the highest to the lowest power die. The random senary number is converted to its decimal equivalent with a calculator.
    Type: Grant
    Filed: August 20, 2001
    Date of Patent: May 6, 2003
    Inventor: Michael Dyer Cuddy